LeMaitre Vascular Inc
NASDAQ:LMAT

Watchlist Manager
LeMaitre Vascular Inc Logo
LeMaitre Vascular Inc
NASDAQ:LMAT
Watchlist
Price: 112.4 USD -1.85% Market Closed
Market Cap: $2.6B

EV/GP

13.3
Current
20%
More Expensive
vs 3-y average of 11.1

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
13.3
=
Enterprise Value
$2.3B
/
Gross Profit
$178.5m

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
13.3
=
Enterprise Value
$2.3B
/
Gross Profit
$178.5m

Valuation Scenarios

LeMaitre Vascular Inc is trading above its 3-year average

If EV/GP returns to its 3-Year Average (11.1), the stock would be worth $93.74 (17% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-61%
Maximum Upside
No Upside Scenarios
Average Downside
37%
Scenario EV/GP Value Implied Price Upside/Downside
Current Multiple 13.3 $112.4
0%
3-Year Average 11.1 $93.74
-17%
5-Year Average 10.5 $88.69
-21%
Industry Average 5.2 $43.62
-61%
Country Average 6.5 $55.15
-51%

Forward EV/GP
Today’s price vs future gross profit

Not enough data available to calculate forward EV/GP

Peer Comparison

All Multiples
EV/GP
P/E
All Countries
Close
Market Cap EV/GP P/E
US
LeMaitre Vascular Inc
NASDAQ:LMAT
2.6B USD 13.3 44.3
US
Intuitive Surgical Inc
NASDAQ:ISRG
165.7B USD 24 58
US
Abbott Laboratories
NYSE:ABT
163B USD 6.4 26
US
Stryker Corp
NYSE:SYK
122.9B USD 8.3 37.9
IE
Medtronic PLC
NYSE:MDT
105.1B USD 5.4 22.8
US
Boston Scientific Corp
NYSE:BSX
86.7B USD 6.7 24.3
US
Edwards Lifesciences Corp
NYSE:EW
47.8B USD 9 43.6
DE
Siemens Healthineers AG
XETRA:SHL
39.8B EUR 5.2 18.7
US
IDEXX Laboratories Inc
NASDAQ:IDXX
45.3B USD 17.2 42.8
US
Becton Dickinson and Co
NYSE:BDX
42.6B USD 5.8 24.2
US
Resmed Inc
NYSE:RMD
31.6B USD 9.3 21.3

Market Distribution

Higher than 78% of companies in the United States of America
Percentile
78th
Based on 9 428 companies
78th percentile
13.3
Low
0 — 4.2
Typical Range
4.2 — 10.6
High
10.6 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 4.2
Median 6.5
70th Percentile 10.6
Max 1 764 211.7

LeMaitre Vascular Inc
Glance View

LeMaitre Vascular Inc., a company engaged in the innovation and marketing of devices for vascular surgeons, traces its roots back to a family enterprise founded on the values of craftsmanship and precision. The company was established in 1983 by George LeMaitre, a preeminent vascular surgeon whose legacy continues to resonate within its core operations. Headquartered in Burlington, Massachusetts, LeMaitre Vascular specializes in developing and selling a variety of products designed to treat peripheral vascular disease. This encompasses conditions that affect blood vessels outside the heart and brain, such as aortic aneurysms and varicose veins. With devices like grafts, patches, and endovascular stent grafts, LeMaitre meets the need for effective surgical tools, facilitating procedures that enhance patient outcomes and surgical efficiency. The company generates revenue primarily through the sale and distribution of its diverse product line to hospitals and surgeons. LeMaitre Vascular leverages a direct sales model, hiring an adept sales force across the globe that builds strong relationships with clinicians. This direct approach is complemented by carefully selected distributors in regions less accessible by its direct sales teams. A key aspect of their strategy is constant innovation, where they thoughtfully assimilate advanced techniques and materials, frequently through strategic acquisitions of smaller firms with promising technologies. This dedication to development, alongside meticulous manufacturing processes, ensures that their offerings remain at the forefront of vascular surgery solutions, thereby sustaining financial growth and a robust competitive edge in a specialized market.

LMAT Intrinsic Value
59.63 USD
Overvaluation 47%
Intrinsic Value
Price $112.4
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett